Lack of Bcl-2 expression in follicular lymphoma may be caused by mutations in the BCL2 gene or by absence of the t(14;18) translocation

Journal of Pathology

Volumn 205, Issue 3, 2005, Pages 329-335

  Schraders, Margit ^a   de Jong, Daphne ^b   Kluin, Philip ^c   Groenen, Patricia ^a   van Krieken, Han ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bcl 2 protein expression; BCL2 gene mutations; FISH; Follicular lymphoma; Translocation t(14; 18)

Indexed keywords

COMPLEMENTARY DNA; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

AMINO ACID SUBSTITUTION; ARTICLE; CANCER GRADING; CHROMOSOME 14Q; CHROMOSOME 18Q; CHROMOSOME TRANSLOCATION 14; CHROMOSOME TRANSLOCATION 18; DNA ISOLATION; DNA SEQUENCE; DNA SYNTHESIS; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABORATORY DIAGNOSIS; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ISOLATION; SEQUENCE ANALYSIS; WESTERN BLOTTING;

BLOTTING, WESTERN; CHROMOSOMES, HUMAN, PAIR 14; CHROMOSOMES, HUMAN, PAIR 18; FALSE NEGATIVE REACTIONS; GENES, BCL-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, FOLLICULAR; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SEQUENCE ANALYSIS, DNA; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 13844253781     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1689     Document Type: Article

References (35)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909-3918.
2. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998; 9: 717-720.
3. Horsman DE, Gascoyne RD, Coupland RW, Coldman AJ, Adomat SA. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol 1995; 103: 472-478.
4. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986; 83: 5214-5218.
5. Cleary ML, Sklar J. Nucleotide sequence of a t(14; 18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985; 82: 7439-7443.
6. Yunis JJ, Oken MM, Kaplan ME, et al. Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma. N Engl J Med 1982; 307: 1231-1236.
7. Cleary ML, Galili N, Sklar J. Detection of a second t(14;18) breakpoint cluster region in human follicular lymphomas. J Exp Med 1986; 164: 315-320.
8. Albinger-Hegyi A, Hochreutener B, Abdou MT, et al. High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am J Pathol 2002; 160: 823-832.
9. Akasaka T, Akasaka H, Yonetani N, et al. Refinement of the BCL2/immunoglobulin heavy chain fusion gene in t(14;18) (q32;q21) by polymerase chain reaction amplification for long targets. Genes Chromosomes Cancer 1998; 21: 17-29.
10. Tsujimoto Y, Bashir MM, Givol I, et al. DNA rearrangements in human follicular lymphoma can involve the 5′ or the 3′ region of the bel-2 gene. Proc Natl Acad Sci USA 1987; 84 1329-1331.
11. Fenton JA, Vaandrager JW, Aarts WM, et al. Follicular lymphoma with a novel t(14;18) breakpoint involving the immunoglobulin heavy chain switch nut region indicates an origin from germinal center B cells. Blood 2002; 99: 716-718.
12. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7: 123-131.
13. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML. Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med 1988; 318 1638-1644.
14. Graninger WB, Seto M, Boutain B, Goldman P, Korsmeyer SJ. Expression of Bcl-2 and Bcl-2-Ig fusion transcripts in normal and neoplastic cells. J Clin Invest 1987; 80: 1512- 1515.
15. Salomons GS, Buitenhuis CK, Martinez MC, et al. Mutational analysis of Bax and Bcl-2 in childhood acute lymphoblastic leukaemia. Int J Cancer 1998; 79: 273-277.
16. Macintyre E, Willerford D, Morris SW. Non-Hodgkin's lymphoma: molecular features of B cell lymphoma. Hematology (Am Soc Hematol Educ Program) 2000; 180-204.
17. Bosga-Bouwer AG, van Imhoff GW, Boonstra R, et al. Follicular lymphoma grade 3B includes 3 cytogenetically defined subgroups with primary t(14;18), 3q27, or other translocations: t(14;18) and 3q27 are mutually exclusive. Blood 2003; 101: 1149-1154.
18. Vaandrager JW, Schuuring E, Raap T, et al. Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 2000; 27 85-94.
19. Haralambieva E. Kleiverda K, Mason DY, Schuuring E, Kluin PM. Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections. J Pathol 2002; 198: 163-170.
20. Yamamoto K, Ichijo H, Korsmeyer SJ. BCL-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G(2)/M. Mol Cell Biol 1999; 19: 8469-8478.
21. Hanada M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of Bel-2 protein: identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995; 270: 11962-11969.
22. Matolcsy A, Casali P, Warnke RA, Knowles DM. Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene. Blood 1996; 88: 3937-3944.
23. Tanaka S, Louie DC, Kant JA, Reed JC. Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas. Blood 1992; 79: 229-237.
24. Matolcsy A, Warnke RA, Knowles DM. Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma. Ann Oncol 1997; 8(Suppl 2): 119-122.
25. Neuberger MS, Enrenstein MR, Klix N, et al. Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunol Rev 1998; 162: 107-116.
26. Storb U, Peters A, Klotz E, et al. Cis-acting sequences that affect somatic hypermutation of Ig genes. Immunol Rev 1998; 162: 153-160.
27. Storb U, Shen HM, Michael N, Kim N. Somatic hypermutation of immunoglobulin and non-immunoglobulin genes. Philos Trans R Soc Lond B Biol Sci 2001; 356: 13-19.
28. Chen HM, Boxer LM. Pi 1 binding sites are negative regulators of bcl-2 expression in pre-B cells. Mol Cell Biol 1995; 15: 3840-3847.
29. Wilson BE, Mochon E, Boxer LM. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 1996; 16: 5546-5556.
30. Heckman CA, Wheeler MA, Boxer LM. Regulation of Bcl-2 expression by C/EBP in t(14;18) lymphoma cells. Oncogene 2003; 22: 7891-7899.
31. Lopez-Guillermo A, Cabanillas F, McDonnell TI, et al. Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma. Blood 1999; 93: 3081-3087.
32. Logsdon MD, Meyn RE Jr, Besa PC, et al. Apoptosis and the Bcl-2 gene family: patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 1999; 44: 19-29.
33. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265-272.
34. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996; 88: 1046-1051.
35. Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152-3162.